• 1
    Fine PEM. Immunities in and to tuberculosis: implications for pathogenesis and vaccination. In: PorterJDH, McAdamPWJ, eds. Tuberculosis back to the future. Chichester: John Wiley & Sons, 1994:53 80.
  • 2
    Dannenberg AM Jr. Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. Immunol Today 1991; 12:228 33.
  • 3
    Bloom BR & Murray CJ. Tuberculosis: commentary on a reemergent killer. Science 1992; 257:1055 64.
  • 4
    MMWRCenters for Disease control and Prevention. Tuberculosis morbidity and mortality—United States. 1992; 42:696 704.
  • 5
    Rodrigues LC & Smith PJ. Tuberculosis in developing countries and methods for its control. Trans R Soc Trop Med Hyg 1990; 84:739 44.
  • 6
    Bloom BR & Fine PEM. The BCG experience: implications for future vaccine against tuberculosis. In: BloomBR, ed. Tuberculosis: pathogenesis, protection and control. Washington, DC: American Society of Microbiology, 1994:531 57.
  • 7
    Palmer CE & Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 1966; 4:553 68.
  • 8
    Cheng SH, Walker KB, Lowrie DB et al. Monocyte antimycobacterial activity before and after Mycobacterium bovis BCG vaccination in Chingleput, India, and London, United Kingdom. Infect Immun 1993; 61:4501 3.
  • 9
    Brown CA, Brown IN, Swinburne R. The effect of oral Mycobacterium vaccae on subsequent responses of mice to BCG sensitization. Tubercle 1985; 66:251 60.
  • 10
    Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698 702.
  • 11
    Hori H, Watanabe F, Sakurai M. Infectious diseases in African children. Acta Paediatr Jpn 1993; 35:553 8.
  • 12
    Bentwich Z, Weisman Z, Moroz C, Bar Yehuda S, Kalinkovich A. Immune dysregulation in Ethiopian immigrants in Israel: relevance to helminth infections? Clin Exp Immunol 1996; 103:239 43.
  • 13
    Yakubovski MV, Varenich SE, Sviziqava AP. Influence of intestinal parasites on postvaccination immunity against bacterial and viral infections. Proc Acad Sciences, Belarus Sci Agriculture, Minsk 1990; 4:101 8.
  • 14
    Azbite M. National tuberculin test survey in Ethiopia. Ethiop Med J 1992; 30:215 323.
  • 15
    World Health Organization. Standard tuberculin test technical guide. Geneva: WHO, 1963.
  • 16
    Sokal J. Measurement of delayed type skin test responses. N Engl J Med 1975; 263:501 2.
  • 17
    Cheesbrough M. Medical laboratory manual for tropical countries, V, 1. Hertford, UK: Stephen Austin and Sons Ltd, 1981.
  • 18
    Das SD, Narayanan PR, Kolappan C, Colston MJ. The cytokine response to Bacille Calmette Guerin vaccination in South India. Int J Tuberc Lung Dis 1998; 10:836 43.
  • 19
    Curry AJ, Else KJ, Jones F, Bancroft A, Grencis RK, Dunne DW. Evidence that cytokine-mediated immune interactions induced by Schistosoma mansoni alter disease outcome in mice concurrently infected with Trichuris muris. J Exp Med 1995; 181:769 74.
  • 20
    Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995; 16:187 91.
  • 21
    Anzala OA, Nagelkerke NJ, Bwayo JJ et al. Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis 1995; 171:686 9.
  • 22
    Rougemont A, Bobson-Pontal ME, Pontal PG et al. Tuberculin skin tests and BCG vaccination in hyperendemic area of onchocerciasis. Lancet 1977; 2:309.
  • 23
    Ottesen EA, Weller PF, Heck L. Specific cellular immune unresponsiveness in human filariasis. Immunology 1977; 33:413 21.
  • 24
    Stewart GR, Boussinesq M, Coulson T et al. Onchocerciasis modulates the immune response to mycobacterial antigens. Clin Exp Immunol 1999; 117:517 23.DOI: 10.1046/j.1365-2249.1999.01015.x
  • 25
    Sartono E, Kruize YC, Kurniawan A et al. Elevated cellular immune responses and interferon-gamma release after long-term diethylcarbamazine treatment of patients with human lymphatic filariasis. J Infect Dis 1995; 171:1683 7.
  • 26
    Vingerhoets J, Dohlsten M, Penne G et al. Superantigen activation of CD4+ and CD8+ T cells from HIV-infected subjects: role of costimulatory molecules and antigen-presenting cells (APC). Clin Exp Immunol 1998; 111:12 19.DOI: 10.1046/j.1365-2249.1998.00465.x
  • 27
    Zumla A & Grange J. Tuberculosis. BMJ 1998; 316:1962 4.
  • 28
    Ellner JJ. The immune response in human tuberculosis—implications for tuberculosis control. J Infect Dis 1997; 176:1351 9.
  • 29
    Barnes PF, Lu S, Abrams JS, Wang E, Yamamura M, Modlin RL. Cytokine production at the site of disease in human tuberculosis. Infect Immun 1993; 61:3482 9.
  • 30
    Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 1995; 273:220 6.
  • 31
    Legesse M. In vitro T-cell proliferation and cytokine production as a surrogate marker for HIV-1 infection progression in Ethiopians.MSc Thesis. Addis Ababa University, 2000.
  • 32
    Bentwich Z, Kalinkovich A, Weisman Z, Borkow G, Beyers N, Beyers AD. Can eradication of worms change the face of AIDS and tuberculosis? Immunol Today 1999; 20:485 735.DOI: 10.1016/s0167-5699(99)01499-1
  • 33
    Tuberculosis prevention Trial, Madras. Trial of BCG vaccines in south India for tuberculosis prevention. Indian J Med Res 1990; 72 (Suppl. 1):1 74.
  • 34
    Ponnighaus JM, Fine PEM, Sterne JA et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992; 339:636 9.